ACSS2 inhibition boosts cabozantinib activity in liver cancer models
Preclinical hepatocellular carcinoma models showed that blocking ACSS2 or autophagy enhanced cabozantinib’s antitumor activity by disrupting a TFEB-linked protective response.
Tag: autophagic flux